Document Detail

Epothilones in the treatment of cancer.
MedLine Citation:
PMID:  16732719     Owner:  NLM     Status:  MEDLINE    
Epothilones are cytotoxic macrolides with a similar mechanism of action to paclitaxel but with the potential advantage of activity in taxane-resistant settings in preclinical models. The epothilones ixabepilone, patupilone, BMS-310705, KOS-862 and ZK-EPO are in early clinical trials for cancer treatment. Phase I studies have shown that dose-limiting toxicities of epothilones are generally neurotoxicity and neutropoenia although initial studies with patupilone indicated that diarrhoea was dose limiting. Neuropathy induced by ixabepilone may be schedule dependent. Over 20 Phase II studies of epothilones in cancer treatment have been reported, and significant activity in taxane-sensitive tumour types (such as breast, lung and prostate cancers) has been noted. Response rates in taxane-refractory metastatic breast cancer are relatively modest, but ixabepilone and patupilone have shown promising efficacy in hormone-refractory metastatic prostate cancer and in taxane-refractory ovarian cancer.
James M G Larkin; Stanley B Kaye
Related Documents :
17315259 - Non platinum metal complexes as anti-cancer drugs.
6758569 - Doxorubicin plus vp-16-213 for the treatment of refractory breast carcinoma.
19139109 - Ixabepilone: targeting betaiii-tubulin expression in taxane-resistant malignancies.
20978159 - Inhalation delivery of a novel diindolylmethane derivative for the treatment of lung ca...
25403569 - Potential microrna-mediated oncogenic intercellular communication revealed by pan-cance...
15477639 - Hypersensitivity reactions to oxaliplatin and the application of a desensitization prot...
20952759 - Characterization of soy-based changes in wnt-frizzled signaling in prostate cancer.
11789549 - Responsiveness of the euroqol in breast cancer patients undergoing high dose chemotherapy.
1860619 - Facts and theories concerning the mechanisms of carcinogenesis.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert opinion on investigational drugs     Volume:  15     ISSN:  1744-7658     ISO Abbreviation:  Expert Opin Investig Drugs     Publication Date:  2006 Jun 
Date Detail:
Created Date:  2006-05-30     Completed Date:  2007-10-26     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9434197     Medline TA:  Expert Opin Investig Drugs     Country:  England    
Other Details:
Languages:  eng     Pagination:  691-702     Citation Subset:  IM    
The Royal Marsden Hospital, Downs Road, Sutton, Surrey, SM2 5PT, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / administration & dosage,  adverse effects,  therapeutic use*
Breast Neoplasms / drug therapy*
Carcinoma, Non-Small-Cell Lung / drug therapy*
Clinical Trials as Topic
Drug Administration Schedule
Drug Evaluation, Preclinical
Drug Resistance, Neoplasm
Epothilones / administration & dosage,  adverse effects,  therapeutic use*
Lung Neoplasms / drug therapy*
Prostatic Neoplasms / drug therapy*
Tubulin Modulators / administration & dosage,  adverse effects,  therapeutic use*
Reg. No./Substance:
0/Antineoplastic Agents; 0/Epothilones; 0/Tubulin Modulators; 0/epothilone B; 219989-84-1/ixabepilone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Recent advances in targeting regulators of apoptosis in cancer cells for therapeutic gain.
Next Document:  INH-A21: a donor-selected Staphylococcal human immune globulin for the prevention of late-onset neon...